Disclaimers & References

1. Data on file, Abbott Diabetes Care, Inc. Data based on the number of users worldwide for FreeStyle Libre family of personal CGMs compared to the number of users for other leading personal CGM brands and based on CGM sales dollars compared to other leading personal CGM brands.

2. Data on file, Abbott Diabetes Care, Inc. 

3. Hilliard, M., et al. Diabetes Technology & Therapeutics. (2019). https:/doi.org/10.1089/dia.2019.0142.

4. Haak, T. Diabetes Therapy (2017). https://doi.org/10.1007/s13300-016-0223-6.

5. Alva, S. J Diabetes Sci Technol (2020): https://doi.org/10.1177%2F1932296820958754.

6. The views, opinions, and positions expressed by FreeStyle Libre systems users are theirs alone, and do not necessarily reflect the views, opinions, and positions of Abbott or any employee thereof. The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary.

7. Fokkert, M. BMJ Open Diab Res Care (2019). https://doi.org/10.1136/bmjdrc-2019-000809.

8. 60-minute warm-up required when applying the sensor.

9. Sensor is water resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

10. Finger pricks are required if glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.

11. Among patient-applied sensors.

14. FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre 3 systems are part of the same family of products.  

15. Data on file, Abbott Diabetes Care, Inc. Based on the reading frequency in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide compared to readings every minute for FreeStyle Libre 2 and FreeStyle Libre 3 systems sensors.

16. Huang, E. Diabetes (2022). https://doi.org/10.2337/db22-73-LB.

17. Unger, J. Postgraduate Medicine (2020). https://doi.org/10.1080/00325481.2020.1744393.

18. Notifications will only be received when alarms settings are enabled and turned on and the sensor is within 20 feet / 6 meters (FreeStyle Libre 2 system) unobstructed of the reading device.

19. All data transferred to LibreView is encrypted using industry-standard SSL/TLS to ensure that it remains private from malicious parties.

20. Campbell, F. M. Pediatric Diabetes (2018). https://doi.org/10.1111/pedi.12735. 

23. Data on file, Abbott Diabetes Care, Inc. Based on the signal strength in Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.

24. LibreView is intended for use by patients, caregivers, and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose device data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

25. To use LibreView, you will need: 1) A computer with a compatible Windows or Mac operating system; 2) The corresponding data cable for the device, if applicable; 3) A compatible glucose monitoring device. LibreView allows you to easily share data with your healthcare professional when you connect with their LibreView Practice. When you are connected to their Practice, any data you upload to LibreView will be automatically stored and visible to your LibreView Care Team.

26. To use LibreView, you will need: 1) A computer with a compatible Windows or Mac operating system; 2) The corresponding data cable for the device, if applicable; 3) A compatible glucose monitoring device. LibreView allows you to easily share data with your healthcare professional when you connect with their LibreView Practice. When you are connected to their Practice, any data you upload to LibreView will be automatically stored and visible to your LibreView Care Team.

27. Evans, M. Diabetes Therapy (2022). https://doi.org/10.1007/s13300-022-01253-9.

28. Bolinder, J. The Lancet (2016). https://doi.org/10.1016/S0140-6736(16)31535-5.

29. 1. Abbott reserves the right to verify the eligibility of participants. 2. Eligible participants should purchase a FreeStyle Libre 2 reader and must present proof of purchase to our experience team. 3. Once the purchase is validated, 1 FreeStyle Libre 2 Plus sensor will be shipped to the participant's address for free. 4. To the extent permissible by law, Abbott shall not be responsible for any loss or damage sustained by a participant while participating in the program, unless such loss or damage is proven to be solely and directly caused by Abbott. 5. These terms and conditions are subject to change without prior notice.  DOH-FDA-CDRRHR Permit No. 0109 s. 2024.

30. FreeStyle Libre 2 User's Manual/Data on file, Abbott Diabetes Care. Inc.

32. Cengiz, Eda, and William V Tamborlane. “A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring.” Diabetes Technology & Therapeutics 11, Suppl 1 (June 2009): S11-6. https://doi.org/10.1089/dia.2009.0002.

38. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166. 

39. Leelarathna, L. New England Journal of Medicine (2022). https://doi.org/10.1056/nejmoa2205650.

40. Leading manufacturers include Accu-Chek, OneTouch and Ascencia.

41. Do not use during xylose absorption testing. Study conducted in 2009. Data on file, Abbott Diabetes Care Inc.

43. For invitro diagnostic use only.

47. The FreeStyle Libre systems apps are designed to facilitate data sharing between patients and their healthcare providers and caregivers. 

201. A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the system or when symptoms do not match the system readings.

202. Based on the Sensor being replaced once every 15 days and scanned at least once every 8 hours.

203. Hortensius, Johanna., et al. Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study. BMC Public Health 12.1 (2012):167.

204. Acetaminophen Interference on ISF Based Glucose Monitoring Systems Alva, S., Chen, T., Naegeli, A. poster presented at DTT 2017.

205. Based on the Sensor being replaced once every 14 days and scanned once every 8 hours.

206. Bailey, et al. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technology & Therapeutics, Volume 17, Number 11, 2015.

207. Rebrin K, Steil GM. Can interstitial glucose assessment replace blood glucose measurements? Diabetes Technol Ther. 2000;2(3):461-472.

208. Rebrin K, Sheppard NF Jr, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and Sensor offset. J Diabetes Sci Technol. 2010;4(5):1087-1098.

209. Data on File, Abbott Diabetes Care Inc, Clinical Report: Evaluation of the Accuracy of the Abbott Sensor-Based Interstitial Glucose Monitoring System 2014.

210. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.

211. Hirsch I and Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? Journal of Diabetes and its Complications, 2005:19:178-181.

212. Kohnert K. Vogt L. Salzsieder E. Advances in understanding glucose variability and the role of continuous glucose monitoring. Eur Endocrinol. 2010: 6:53-56.

213. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol & Ther. 2013;15(3):198-211. Data on file. In a study conducted by Abbott Diabetes Care, 93.4% of patients surveyed (n=30) did not feel discomfort under the skin while wearing the Sensor.

212. Study data was collected with US FreeStyle Libre 2 system and is applicable to the FreeStyle Libre and FreeStyle Libre 3 system based on technological similarities.

213. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Diet, Eating, & Physical Activity. 2016. Accessed 28 May 2023. Available at: https://www.niddk.nih.gov/health-information/diabetes/overview/diet-eating-physical-activity

214. Joseph JJ, Golden SH. Ann NY Acad Sci. 2017;1391(1):20–34.

215. van Duinkerken E, et al. Diabet Med. 2020;37(4):555–563.

216. Wright E, et al. Diabetes Spectrum. 2021;34(2):184–189

217. Charleer S, et al. Diabetes Care 2020;43(2):389-397

218. Hirst JA, et al. Diabetes Care. 2012;35(2):446–454.

219. Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: 80th Scientific Sessions of the American Diabetes Association; June 12-16, 2020;Virtual.

220. Results from the SELFY Study for diabetes self-management with children (4-12 years) and teenagers (13-17 years), children aged 4-12, a caregiver at least 18 years old is responsible for supervising, managing, and assisting them in using the FreeStyle Libre system and interpreting its readings.

221. Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 system has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.

222. Scott EM, et al. Diabetes Technol Ther 2018;20(3):180-188.